You are leaving Relmada.com
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?
Relmada (NASDAQ: RLMD) is a late-stage biotech company focused upon addressing diseases of the central nervous symptom (CNS) in an entirely new way. Our lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission and is in development for both the adjunctive or monotherapy treatment of major depressive disorder (MDD). Data from the Phase 2 trial with REL-1017 suggest rapid and sustained antidepressant effects with statistically significant improvements as compared to placebo on all measured efficacy measures. The Phase 2 study data also suggest a favorable safety and tolerability profile of REL-1017 relative to placebo-treated patients on a background of anti-depressant therapy (ADT). The U.S. Food and Drug Administration has granted Fast Track designation for REL-1017 as an adjunctive treatment of MDD. Reliance I, the first pivotal trial, was initiated in December 2020, and Reliance II and Reliance-OLS were underway in April 2021 and are ongoing. Reliance III, studying REL-1017 as a monotherapy, was initiated in July 2021 and is ongoing.